[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Dartnell J, Pilling J, Ferner R, Cane P, Lang-Lazdunski L: Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor. J Thorac Oncol; 2009 Jan;4(1):135-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor.
  • Malignant triton tumor is a divergent malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation.
  • We report a case of malignant triton tumor arising in the brachial plexus of a 28-year-old women with neurofibromatosis type 1.
  • Fluorodeoxyglucose-positron emission tomography-computed tomography before excision demonstrated a tumor with a maximum standard uptake value of 21 at 4 hours postinjection.
  • The patient underwent complete excision of the tumor through median sternotomy and left supraclavicular approach.
  • Adjuvant radiotherapy and chemotherapy were planned but the patient died of metastatic disease within 3 months of surgical resection.
  • [MeSH-major] Brachial Plexus / pathology. Neurilemmoma / diagnosis. Pancoast Syndrome / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neurofibromatosis 1 / complications. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096322.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Ye C, Xi PC, Hu XG: Clinical analysis of uncinate process carcinoma of the pancreas. Hepatobiliary Pancreat Dis Int; 2003 Nov;2(4):605-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyse the clinical features of uncinate process carcinoma of the pancreas and the diagnosis and treatment of this malignancy.
  • Thirty-seven patients received regional pancreaticoduodenectomy (RP), 16 partial resection of the superior mesenteric vein-portal vein (SMV-PV) or superior mesenteric artery (SMA) and reconstruction, 1 anhydrous alcohol injection in the celiac nerve plexus, regional chemotherapy via a chemotherapy pump, and liver biopsy, and 5 no operation.
  • The survival of the patients after operation was 2-46 months (median 12.1 months).
  • CONCLUSIONS: Pancreas uncinate process carcinoma invading the adjacent SMV/SMA-PV causes difficulty in early diagnosis and poor prognosis, which are related to its location, not tumor's aggressive nature.
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14627529.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Truilhe Y, Richaud P, Houliat T, Lagarde P, Demeaux H, Stoll D, Darrouzet V: [Surgical methods of removal of T4 nasopharyngeal malignancies. A preliminary report on 18 cases]. Ann Otolaryngol Chir Cervicofac; 2002;119(3):138-45
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Place de la chirurgie dans le traitement des cancers du cavum classés T4.
  • Three patients were non-responders to neoadjuvant chemotherapy, 6 suffered local recurrence following standard treatment and 7 were operated first either because of a huge and osteolytic tumor or because of an uncommon histolopathology.
  • RESULTS: Preoperative Vth nerve neuralgia (8 cases) was alleviated (4 cases) or cured (3 cases).
  • At the time of diagnosis, ophthalmoplegia was observed in 3 cases.
  • It disappeared postoperatively in 2 cases and after following radiation therapy in one.
  • Median follow-up of the series was of 31.8 mths.
  • The 13 last (72.2%) are alive without disease with a 35.6 mths median follow-up (6-77 mths).
  • CONCLUSION: In selected cases surgical treatment does not demonstrate any toxicity and is able to offer mid-term local control of the disease.
  • Its role is to be evaluated further before inclusion in the therapeutic algorithm of these very bad prognosis-associated tumors.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Preoperative Care. Prognosis. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12218867.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Balaguer J, Wilson MW, Billups CA, Mancini J, Haik BG, Qaddoumi I, Khoury JD, Rodriguez-Galindo C: Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments. Pediatr Blood Cancer; 2009 Mar;52(3):351-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments.
  • BACKGROUND: The impact of chemotherapy, focal therapies, radiation and co-existing ocular morbidities on histology of eyes with retinoblastoma enucleated following chemoreduction is not well known.
  • PROCEDURE: Twenty-five eyes (23 patients) with retinoblastoma enucleated after failing eye-salvage therapy were evaluated.
  • All specimens were reviewed for evidence of ciliary body, choroidal, optic nerve, and scleral invasion.
  • RESULTS: The median age at diagnosis was 14 months (range, 1-37 months).
  • Twenty eyes were classified as Reese-Ellsworth Group IV-V at diagnosis.
  • Histologic findings included choroidal invasion (n = 7), ciliary body invasion (n = 4), optic nerve invasion (n = 6) and scleral invasion (n = 3).
  • The median time from diagnosis to enucleation was 11 months.
  • Co-existing retinal detachment and vitreous hemorrhage significantly increased the likelihood of optic nerve invasion (P = 0.014 and P = 0.011, respectively).
  • Prolonged time to enucleation was significantly associated with the likelihood of choroidal (P = 0.010) and ciliary body (P = 0.021) invasion as well as invasion of multiple sites.
  • CONCLUSION: In eyes with retinoblastoma enucleated after chemoreduction, co-existing ocular morbidities and time to enucleation are predictive of extra-retinal extension.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021223.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / PHS HHS / / 21765; United States / NCI NIH HHS / CA / CA 23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS124023; NLM/ PMC4643656
  •  go-up   go-down


5. Juhász M, Nitsche B, Malfertheiner P, Ebert MP: Implications of growth factor alterations in the treatment of pancreatic cancer. Mol Cancer; 2003 Jan 7;2:5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of growth factor alterations in the treatment of pancreatic cancer.
  • Pancreatic cancer ranks fifth as a cause of cancer-related death in the world with an overall 5-year survival rate of less than 1% and a median survival of less than a year after tumour detection.
  • Most of these patients have already metastases at the time of diagnosis.
  • The oncologic strategies such as chemotherapy, radiotherapy, antihormonal modalities or the systemic use of specific monoclonal antibodies have not achieved a significant improvement in the survival of pancreatic cancer patients.
  • The molecular knowledge regarding changes in the expression of growth factors in pancreatic cancer has the potential to improve diagnostic and therapeutic treatment strategies in the near future.
  • [MeSH-major] Growth Substances / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Animals. Epidermal Growth Factor / metabolism. Fibroblast Growth Factors / metabolism. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Nerve Growth Factor / metabolism. Platelet-Derived Growth Factor / metabolism. Transforming Growth Factor beta / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Aug 1;54(15):3959-62 [8033121.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Int J Cancer. 1995 Sep 4;62(5):529-35 [7665222.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5545-7 [7585631.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1124-6 [9515793.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):798-807 [9516401.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7495-500 [9516449.001]
  • [Cites] Int J Pancreatol. 1998 Apr;23(2):83-100 [9629506.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 16;255(2):268-73 [10049697.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1553-63 [10188906.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5363-72 [10498890.001]
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33637-43 [10559252.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2419-28 [10561305.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1936-48 [10815919.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2926-35 [10850439.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7163-9 [11156426.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):105-12 [11205897.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):361-9 [11291072.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4885-91 [11406567.001]
  • [Cites] Int J Oncol. 2001 Jul;19(1):71-81 [11408925.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2563-72 [11489840.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1162-5 [11490824.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):488-99 [11505392.001]
  • [Cites] J Histochem Cytochem. 2001 Oct;49(10):1205-10 [11561004.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7518-24 [11606388.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):3-8 [11740801.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):27-33 [11740804.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1702-6 [11912143.001]
  • [Cites] Pancreatology. 2001;1(4):343-55 [12120213.001]
  • [Cites] Pancreatology. 2001;1(5):517-24 [12120231.001]
  • [Cites] Pancreas. 2002 Aug;25(2):111-21 [12142732.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1037-41 [2659539.001]
  • [Cites] J Clin Invest. 1990 Mar;85(3):916-20 [2155930.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5087-92 [1655243.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1076-82 [1764370.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):1006-12 [1310635.001]
  • [Cites] Oncogene. 1993 Feb;8(2):289-98 [8426738.001]
  • [Cites] Cancer Lett. 1993 May 14;69(3):151-60 [8513440.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5087-9 [8221640.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1846-56 [8253361.001]
  • [Cites] Lab Invest. 1993 Dec;69(6):682-9 [8264231.001]
  • [Cites] Nature. 1994 Feb 3;367(6462):474-6 [8107807.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1645-51 [8194712.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1254-62 [9797382.001]
  • [Cites] J Clin Invest. 1998 Nov 1;102(9):1662-73 [9802880.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1998;8(3-4):377-93 [9807701.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1413-20 [9815939.001]
  • [Cites] Front Biosci. 1998 Nov 15;3:D1148-60 [9820739.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 Dec;10(12):1025-9 [9895049.001]
  • (PMID = 12537586.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Platelet-Derived Growth Factor; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 62031-54-3 / Fibroblast Growth Factors; 62229-50-9 / Epidermal Growth Factor; 9061-61-4 / Nerve Growth Factor
  • [Number-of-references] 60
  • [Other-IDs] NLM/ PMC149419
  •  go-up   go-down


6. Dunkel IJ, Chan HS, Jubran R, Chantada GL, Goldman S, Chintagumpala M, Khakoo Y, Abramson DH: High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer; 2010 Jul 15;55(1):149-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.
  • Here we describe a series of eight patients treated with intensive chemotherapy, defined as the intention to include high-dose chemotherapy with autologous hematopoietic stem cell rescue.
  • PROCEDURE: Induction chemotherapy included cyclophosphamide and/or carboplatin with a topoisomerase inhibitor.
  • High-dose chemotherapy regimens were carboplatin and thiotepa with or without etoposide (n = 3) or carboplatin, etoposide, and cyclophosphamide (n = 2).
  • RESULTS: Seven patients had leptomeningeal disease and one patient had only direct extension to the CNS via the optic nerve.
  • Three patients had stage 4b disease at the time of original diagnosis of the intra-ocular retinoblastoma; five had later onset at a median of 12 months (range 3-69 months).
  • One patient died of toxicity (septicemia and multi-organ system failure) during induction and two had disease progression prior to high-dose chemotherapy.
  • Five patients received high-dose chemotherapy at a median of 6 months (range 4-6) post-diagnosis of stage 4b disease.
  • Two patients survive event-free at 40 and 101 months; one was irradiated following recovery from the high-dose chemotherapy.
  • CONCLUSIONS: Intensive multimodality therapy may be beneficial for some patients with stage 4b retinoblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Retinal Neoplasms / therapy. Retinoblastoma / therapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Transplantation, Autologous

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486181.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • The median age was 37 years [range: 13-64], the male/female ratio was 1:1.
  • Two patients suffered from Neurofibromatosis type 1.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • INTERPRETATION: MPNST is a rare and fatal diagnosis in neurosurgery with high risk of local recurrence and occurence of distant metastases.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / surgery. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / surgery. Thoracic Neoplasms / mortality. Thoracic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


8. Salonia A, Gallina A, Briganti A, Colombo R, Bertini R, Da Pozzo LF, Zanni G, Sacca A, Rocchini L, Guazzoni G, Rigatti P, Montorsi F: Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. J Sex Med; 2010 Jan;7(1 Pt 1):149-55
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy.
  • AIMS: To assess OF over time in patients who underwent bilateral nerve-sparing radical retropubic prostatectomy (BNSRRP) for organ-confined prostate cancer (PCa).
  • Multivariate linear regression analysis (MVA) of the association between predictors (patient's age, IIEF-erectile function [EF], ICIQ-SF, and the use of postoperative proerectile pharmacological treatments) and the IIEF-OF at 12-month, 24-month, and 36-month FU.
  • RESULTS: Preoperative mean (median) IIEF-OF was 7.6 (10).
  • The 12-month MVA showed that while proerectile oral therapy did not affect postoperative OF (P = 0.150; Beta 0.081), IIEF-OF linearly increased with IIEF-EF (P < 0.001; Beta 0.425).
  • The 24-month and 36-month analyses showed that IIEF-OF still linearly increased with IIEF-EF (P < 0.001; Beta 0.540, and P < 0.001; Beta 0.536 respectively at the 24- and 36-month FU), whereas pharmacological therapy, rate of urinary continence, and patient's age did not significantly affect postoperative OF.
  • CONCLUSIONS: Postoperative OF significantly ameliorates over time in patients undergoing BNSRRP.
  • The higher the postoperative EF score, the higher the OF throughout the FU time frame.
  • [MeSH-minor] Aged. Erectile Dysfunction / diagnosis. Erectile Dysfunction / epidemiology. Erectile Dysfunction / psychology. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life / psychology. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796018.001).
  • [ISSN] 1743-6109
  • [Journal-full-title] The journal of sexual medicine
  • [ISO-abbreviation] J Sex Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Ye C, Xi P, Hu X: [Uncinate process carcinoma of the pancreas: clinical features and diagnosis and treatment]. Zhonghua Wai Ke Za Zhi; 2002 Oct;40(10):766-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncinate process carcinoma of the pancreas: clinical features and diagnosis and treatment].
  • OBJECTIVE: To summarize the clinical features and diagnosis and treatment of uncinate process carcinoma of the pancreas.
  • Alcohol injection was made in the nerve plexus of the trunks of both celic axes and the superior mesenteric artery and regional chemotherapy via chemotherapy pump and liver biopsy in one case.
  • Postoperation survival 2 - 44 months and was 1 the median survival was 11.2 months.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12487881.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Snady H: Interventional endoscopy, neoadjuvant therapy and the gastroenterologist. Hematol Oncol Clin North Am; 2002 Feb;16(1):53-79
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.
  • With current treatment, survival of greater than 1 year should be anticipated for many patients with pancreatic cancer.
  • Relief of biliary obstruction allows improvement in liver function and more time to evaluate tumor stage accurately to determine initial treatment (see Fig. 1).
  • A cost-effective algorithm to determine accurate stage and treatment can start with the size of the mass on initial imaging studies.
  • EUS-guided FNA represents a significant improvement over CT scan-guided FNA to make a tissue diagnosis.
  • Tumors reliably staged as unresectable by nonoperative imaging methods including EUS are treated with chemotherapy with or without concurrent radiotherapy because median survival of these patients is 2 years in some series.
  • For chronic pain or gastric outlet obstruction not responding or treatable by chemoradiotherapy, endoscopically guided celiac plexus nerve block and stenting improve the quality of life for patients with pancreatic cancer.
  • Rather than reliance on any single standard, clinical judgment and communication among the team are paramount to providing optimal care for patients with a pancreatic neoplasm.
  • [MeSH-major] Adenocarcinoma / therapy. Endoscopy. Endoscopy, Gastrointestinal. Endosonography. Neoadjuvant Therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Ampulla of Vater / surgery. Antineoplastic Agents / therapeutic use. Autonomic Nerve Block / methods. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Chemotherapy, Adjuvant. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Cholestasis / therapy. Combined Modality Therapy. Common Bile Duct Neoplasms / surgery. Diagnostic Imaging / methods. Gastric Outlet Obstruction / surgery. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Pain Management. Palliative Care. Pancreatic Cyst / therapy. Prognosis. Radiotherapy, Adjuvant. Stents

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 115
  •  go-up   go-down


11. Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH: Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol; 2004 Jan;66(1-2):167-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the exception of 1 patient, the primary gastric cancer was Borrmann type III or IV, and 88% had poorly differentiated or signet-ring cell histology.
  • Eighty percent of the patients had multiple neuraxis syndrome, and the combination of brain plus cranial nerve syndrome was the most common manifestation.
  • Computed tomography (CT) findings were abnormal in a minor proportion of the patients, while magnetic resonance imaging (MRI) revealed abnormality in 67% of the patients, which could help the diagnosis.
  • Median survival was very short, 4 weeks.
  • By univariate analysis, good performance status, intrathecal chemotherapy, and low CSF LDH concentration favored survival.
  • Multivariate analysis revealed that the administration of CSF chemotherapy was the independent prognostic factor for survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Cranial Nerve Neoplasms / pathology. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Nervous System Diseases / etiology. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol (Napoli). 1976 May-Jun;31(3):262-9 [1015368.001]
  • [Cites] Arch Neurol. 1988 Jul;45(7):741-4 [3390029.001]
  • [Cites] Cancer. 1986 Dec 15;58(12 ):2656-61 [3779615.001]
  • [Cites] Pathol Res Pract. 1991 Mar;187(2-3):341-5; discussion 345-7 [2068018.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):103-10 [9696359.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):771-6 [10622506.001]
  • [Cites] Neurol Med Chir (Tokyo). 1979 Jan;19(1):39-44 [84354.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Arch Neurol. 1998 Apr;55(4):506-12 [9561978.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [Cites] Gastroenterol Clin Biol. 2001 Apr;25(4):422-4 [11449130.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):122-37 [4405841.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1462-6 [1515997.001]
  • [Cites] Clin Neurol Neurosurg. 1992;94(3):235-40 [1327614.001]
  • [Cites] Arch Neurol. 1994 May;51(5):457-61 [8179494.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Cancer. 1951 May;4(3):610-8 [14839615.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):225-9 [2086737.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):55-64 [9266441.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • [Cites] Ann Neurol. 1995 Jul;38(1):51-7 [7611725.001]
  • [Cites] J Neurooncol. 1999 May;43(1):59-62 [10448872.001]
  • [Cites] Surgery. 1990 Feb;107(2):140-8 [1689080.001]
  • [Cites] Surg Today. 2000;30(6):485-90 [10883456.001]
  • [Cites] Neurology. 1955 Oct;5(10):706-22 [13265982.001]
  • [Cites] South Med J. 1979 Aug;72(8):930-2 [472815.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):245-52 [9696379.001]
  • (PMID = 15015782.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Cuccia V, Galarza M: Pure pineal germinomas: analysis of gender incidence. Acta Neurochir (Wien); 2006 Aug;148(8):865-71; discussion 871

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Of a total of 50 germ cell tumors operated on between 1988 and 2004 we found 26 cases (median age at diagnosis, 12 years) of pineal germ cell tumors.
  • In pure pineal germinomas, the main clinical presentations were intracranial hypertension and cranial nerve dysfunction.
  • Imaging studies disclosed a homogeneous type of tumor (n = 10) and associated hydrocephalus (n = 6).
  • Cases were managed with biopsy and subsequent radiation therapy and chemotherapy.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Argentina / epidemiology. Cerebrospinal Fluid Shunts / standards. Cerebrospinal Fluid Shunts / statistics & numerical data. Child. Cranial Nerve Diseases / diagnosis. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / physiopathology. Drug Therapy / standards. Drug Therapy / statistics & numerical data. Female. Humans. Hydrocephalus / diagnosis. Hydrocephalus / etiology. Hydrocephalus / physiopathology. Intracranial Hypertension / diagnosis. Intracranial Hypertension / etiology. Intracranial Hypertension / physiopathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / therapy. Radiotherapy / standards. Radiotherapy / statistics & numerical data. Sex Distribution. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791430.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


13. Keyaki A, Nabeshima S, Hashimoto S, Waga S: [Clinical problems in the treatment of primary central nervous system malignant lymphoma]. No To Shinkei; 2000 Sep;52(9):781-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical problems in the treatment of primary central nervous system malignant lymphoma].
  • While the treatment of extracerebral lymphomas with the combination of chemotherapy and radiotherapy has drastically improved outcomes, the treatment of primary central nervous system malignant lymphoma(PCNSML) has been disappointing.
  • Because of the variety of clinical presentations, progression of disease, and treatment modalities, careful inspection of factors which influence survival may suggest possible approaches for a more effective management in each case.
  • In this report, clinical problems in the treatment of PCNSML was discussed with presenting cases experienced at Tenri hospital since 1983.
  • All patients received radiation therapy.
  • Various modality of chemotherapy was performed in 14 cases.
  • The median survival time was estimated to be 15 months.
  • Among the 9 patients alive at last contact the median length of follow up was 31.5 months(range 4 to 56 months).
  • 1) varieties of initial clinical presentations, 2) variable recurrence patterns, metastases including CSF dissemination and extracranial metastases, 3) treatment-related leukoencephalopathy.
  • [MeSH-major] Brain Neoplasms / therapy. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Diagnosis, Differential. Encephalitis, Herpes Simplex / diagnosis. Female. Humans. Male. Middle Aged. Multiple Sclerosis / diagnosis. Neoplasm Seeding. Prognosis. Survival Rate


14. BenJelloun H, Jouhadi H, Maazouzi A, Benchakroun N, Acharki A, Tawfiq N, Sahraoui S, Benider A: [Rhabdomyosarcoma of the salivary glands. Report of 3 cases]. Cancer Radiother; 2005 Sep;9(5):316-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The third patient had a locally advanced tumour and received chemotherapy followed by radiotherapy.
  • Loco-regional recurrence was observed in all cases and median survival was 12 months.
  • Treatments include surgery and radiotherapy.
  • The role of chemotherapy remains to be discussed.
  • [MeSH-major] Parotid Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis
  • [MeSH-minor] Adolescent. Aged. Chemotherapy, Adjuvant. Child. Facial Nerve / pathology. Facial Paralysis / etiology. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953749.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Fenton S, Kemp EG, Harnett AN: Screening for ophthalmic involvement in asymptomatic patients with metastatic breast carcinoma. Eye (Lond); 2004 Jan;18(1):38-40
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recognition and early treatment of both ocular metastases and ocular manifestations of metastatic breast carcinoma are important in maximising the quality of life in this group of palliative patients.
  • RESULTS: The median time from diagnosis of breast carcinoma to ophthalmic screening was 5 years (range 6 months-23 years).
  • Four patients (5.8%) had ophthalmic manifestations of metastatic breast carcinoma and a further two had ocular complications of treatment.
  • One patient had a restrictive motility problem from a metastatic deposit to her lateral rectus muscle and another had corneal punctate epitheliopathy secondary to a seventh nerve palsy.
  • In addition, two patients had symptomatic dry eyes whose onset coincided with commencement of chemotherapy.
  • [MeSH-major] Breast Neoplasms. Eye Neoplasms / diagnosis. Eye Neoplasms / secondary. Mass Screening
  • [MeSH-minor] Adult. Aged. Eye Diseases / etiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pilot Projects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eye (Lond). 2004 Jan;18(1):1-2 [14707955.001]
  • (PMID = 14707963.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Hu Y, Lu T, Mai W, Han F, Huang Y, Liu H, Zhang E: [Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec;36(6):463-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the long-term outcome and prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma (NPC) after initial radiation therapy.
  • METHODS: From January 1985 to December 1986, 100 patients (71 male, 29 female) with the diagnosis of NPC were found to have skull base erosion from computed tomography (CT).
  • Ninety-six patients had World Health Organization (WHO) type III undifferentiated carcinoma while four had type I carcinomas.
  • All patients underwent external beam radiotherapy alone to 66-80 Gy over 6-8 weeks.
  • Daily fraction size of 2 Gy was delivered utilizing cobalt-60 or linear accelerator.
  • No patient received chemotherapy.
  • Median follow-up was 22.3 months (2 months-174 months).
  • However, in the sub-group of patients with both anterior cranial nerves (I-VIII) and posterior cranial nerve (IX-XII) involvement had a five-year survival of only 7.7%.
  • After multivariate analysis, complete recovery of cranial nerve involvement, cranial nerves palsy and recovery of headache after irradiation were found to be independent prognostic factors in this cohort.
  • It demonstrates the importance of cranial nerves involvement as well as recovery of headache and cranial nerve palsy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Nasopharyngeal Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Cranial Nerve Injuries. Factor Analysis, Statistical. Female. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12761966.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Raney RB, Meza J, Anderson JR, Fryer CJ, Donaldson SS, Breneman JC, Fitzgerald TJ, Gehan EA, Michalski JM, Ortega JA, Qualman SJ, Sandler E, Wharam MD, Wiener ES, Maurer HM, Crist WM: Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol; 2002 Jan;38(1):22-32
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997.
  • BACKGROUND: We reviewed 611 patients with parameningeal sarcoma entered on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-II through IV (1978-1997), to delineate treatment results and evaluate prognostic factors.
  • PROCEDURE: Primary sites were the middle ear/mastoid (N = 138), nasopharynx/nasal cavity (N = 235), paranasal sinuses (N = 132), parapharyngeal region (N = 29), and the pterygopalatine/infratemporal fossa (N = 77).
  • Treatment was initial biopsy or surgery followed by multiagent chemotherapy and radiation therapy (XRT).
  • Beginning in 1977, patients with cranial nerve palsy, cranial base bony erosion, and/or intracranial extension at diagnosis were considered as having meningeal involvement.
  • They received triple intrathecal medications, whole brain XRT, and then spinal XRT.
  • These treatments were successively eliminated from 1980 to 1991.
  • Favorable prognostic factors were: age 1-9 years at diagnosis; primary tumor in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal areas; no meningeal involvement; and non-invasive tumors (T1).
  • Thirty-five of 526 patients (6.7%) with information about presence/absence of meningeal involvement at diagnosis developed central nervous system (CNS) extension at 5-164 weeks (median, 46 weeks) after starting therapy.
  • CONCLUSIONS: Biopsy, XRT to the target volume, and systemic chemotherapy are successful treatments for the large majority of patients with localized parameningeal sarcoma.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Meningeal Neoplasms / therapy. Outcome Assessment (Health Care). Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clinical Protocols. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Infant, Newborn. Injections, Spinal. Male. Methotrexate / administration & dosage. Neoplasm Invasiveness. Prognosis. Radiation Dosage. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley‐Liss, Inc.
  • (PMID = 11835233.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether diagnosis of asymptomatic recurrence after RC by routine follow-up investigations confers a survival benefit versus symptomatic recurrence.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • In multivariable analysis, mode of recurrence diagnosis and site of initial recurrence were the only independent predictors of CSS and OS.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Oct;58(4):495-7 [20609511.001]
  • (PMID = 20541311.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD: The role of palliative radiosurgery when cancer invades the cavernous sinus. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):709-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the role of stereotactic radiosurgery (SRS) in the treatment of patients who developed cavernous sinus metastases or direct invasion.
  • The median patient age was 57.8 years.
  • Previous adjuvant management included fractionated radiotherapy in 8, chemotherapy in 16, and both radiotherapy and chemotherapy in 5.
  • The median target volume was 6.3 cm(3) (range, 0.3-33.6), and the median margin dose was 14 Gy (range, 12-20).
  • SRS early after diagnosis was significantly associated with improvement of cranial nerve dysfunction.
  • The benefits for cranial nerve deficits are best when SRS is performed early.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Cranial Nerve Diseases / etiology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Palliative Care. Radiotherapy Dosage. Retrospective Studies. Skull Base Neoplasms / secondary

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692328.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Edelweiss M, Malpica A: Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol; 2010 Mar;34(3):393-400
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor size ranged from 1.2 to 15 cm (median, 4 cm).
  • Of interest, in 7 of our 13 cases, a variety of diagnoses, such as cellular dermatofibroma, cellular leiomyoma, neurofibroma, low-grade leiomyosarcoma, fibrosarcoma, low-grade malignant schwannoma, desmoplastic melanoma, cellular neurofibroma, and low-grade malignant peripheral nerve sheet tumor were initially considered.
  • One patient also developed distant metastases.
  • All recurrences were treated surgically; 1 patient also received chemotherapy and radiotherapy and another received imatinib (Gleevec).
  • [MeSH-major] Biomarkers, Tumor / analysis. Dermatofibrosarcoma / diagnosis. Immunohistochemistry. Skin Neoplasms / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Radiotherapy, Adjuvant. Reoperation. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139758.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Noto Y, Shiga K, Fujinami J, Mizuno T, Nakagawa M, Tanaka K: [Subacute sensory neuronopathy associated with squamous cell carcinoma of the lung: a case report]. Rinsho Shinkeigaku; 2009 Aug;49(8):497-500
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 59-year-old man who developed dysesthesia in all extremities with severe loss of deep sensation over three months.
  • The nerve conduction study barely elicited sensory nerve action potentials both in the median and in the sural nerve.
  • The subsequent chemotherapy and radiation therapy for the neoplasm improved the radicular pain and the deep sensation to a moderate extent, leading to the diagnosis of paraneoplastic subacute sensory neuropathy (SSN).
  • The early detection and the treatment of the primary tumor are crucial in a patient with subacute progression of sensory-dominant neuropathy.
  • [MeSH-minor] Combined Modality Therapy. Early Diagnosis. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - neuronopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827601.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Zhang WC, Cheng JP, Li Q, Zhang L, Wang XD, Anniko M: Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases. Acta Otolaryngol; 2009 Nov;129(11):1320-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of malignant tumour should be based on extensive invasion of neighbouring organs and distant metastasis.
  • Radiotherapy is effective, whereas chemotherapy is uncertain.
  • OBJECTIVE: To summarize the clinical pathological and prognostic characteristics of MCBT and explore methods for diagnosis and treatment.
  • MATERIALS AND METHODS: The study material comprised clinical, pathological, therapeutic and follow-up data concerning nine patients (four males, five females) with MCBT, treated at Tianjin Cancer Hospital between January 1956 and June 2006.
  • Shamblin classification was: one case, type II; 8 cases, type III.
  • Eight patients suffered from a cranial nerve dysfunction (defect) and two suffered postoperatively from a hoarse voice, four had a glossal deviation, five had Horner's syndrome and one had a deviation of the lip angle.
  • The histopathological diagnosis in all nine cases was MCBT.
  • The median follow-up period was 3 years (range 6 months to 14 years).
  • [MeSH-minor] Adult. Carotid Arteries / pathology. Carotid Arteries / surgery. Combined Modality Therapy. Cranial Nerves / pathology. Disease Progression. Disease-Free Survival. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Postoperative Complications / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863331.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve; 2001 Aug;24(8):1050-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
  • NCS included recording of sensory nerve action potentials (SNAPs) from median, radial, ulnar, and sural nerves.
  • SNAP amplitudes for each nerve were expressed as the percentage of its baseline, and the mean of the four was termed the SNAP index.
  • Thalidomide was discontinued in 55 patients for lack of therapeutic response.
  • Six patients developed neuropathy.
  • The SNAP index can be used to monitor peripheral neuropathy, but not for early detection.
  • [MeSH-major] Peripheral Nervous System Diseases / chemically induced. Peripheral Nervous System Diseases / diagnosis. Prostatic Neoplasms / drug therapy. Thalidomide / adverse effects
  • [MeSH-minor] Action Potentials / drug effects. Age Factors. Aged. Aged, 80 and over. Brachial Plexus / drug effects. Brachial Plexus / physiopathology. Cohort Studies. Dose-Response Relationship, Drug. Electrodiagnosis. Electromyography. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neural Conduction / drug effects. Neurons, Afferent / drug effects. Prospective Studies. Risk Factors. Sural Nerve / drug effects. Sural Nerve / physiopathology


24. Ozyar E, Gurkaynak M, Yildiz F, Atahan IL: Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival. Radiother Oncol; 2004 Jul;72(1):71-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their ages ranged from 9 to 72 years (median age: 43.5).
  • Histopathological diagnosis was WHO 2 and 3 in 89 (93%) patients.
  • All patients were treated with external radiotherapy and 77 out of 96 patients (80%) with stage IV disease received either concomitant or neoadjuvant cisplatin based combined chemotherapy regimens.
  • Median follow-up time was 30 months (range: 4-101 months).
  • RESULTS: At the time of this analysis, 60 (62%) patients were alive and 48 of them were free of disease.
  • DMFS was adversely affected by the presence of cranial nerve palsy at diagnosis (P=0.01), advanced T status (P=0.03) and advanced N status (P=0.0003).
  • In univariate analysis treatment with chemotherapy was found to be an unfavorable prognostic factor for DMFS (P=0.02).
  • Patients treated with chemotherapy as an adjuvant to radiotherapy had tended to have a better DFS (P=0.04).
  • CONCLUSIONS: The local relapse was the major cause of failure in patients with stage IVA disease, and distant metastasis was the predominant treatment failure in stage IVB patients.
  • While stage IVA patients may benefit more intensive local treatment strategies, stage IVB patients definitely need more systemic treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local. Neoplasm Staging
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15236877.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Lu TX, Mai WY, Teh BS, Hu YH, Lu HH, Chiu JK, Carpenter LS, Woo SY, Butler EB: Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):589-98
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: From January 1985 to December 1986, 100 patients (71 males, 29 females) with a diagnosis of nasopharyngeal carcinoma were found on computed tomography (CT) to have skull base erosion.
  • Ninety-six patients had World Health Organization type III undifferentiated carcinoma, and 4 had type I.
  • All patients underwent external beam RT (EBRT) alone to 66-80 Gy during 6-8 weeks.
  • A daily fraction size of 2 Gy was delivered using 60Co or a linear accelerator.
  • No patient received chemotherapy.
  • The median follow-up was 22.3 months (range 2-174).
  • However, the subgroup of patients with both anterior cranial nerve (I-VIII) and posterior cranial nerve (IX-XII) involvement had a 5-year survival of only 7.7%.
  • A difference in the time course of local recurrence and distant metastasis was observed.
  • After multivariate analysis, complete recovery of cranial nerve involvement, cranial nerve palsy, and headache after irradiation were found to be independent prognostic factors in this cohort.
  • Our results demonstrate the importance of cranial nerve involvement, recovery of headache, and cranial nerve palsy.
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Proportional Hazards Models. Skull Base / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11597797.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement